Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma
© 2015 Wiley Periodicals, Inc..
We retrospectively reviewed the results of cyclophosphamide (3 g/m(2) ), doxorubicin and dexamethasone plus granulocyte-colony stimulating factor (G-CSF) (ID-CY/DOX group), low-dose cyclophosphamide (2 g/m(2) ) plus G-CSF (LD-CY group) and G-CSF alone (G-CSF group) for stem cell mobilization in patients with multiple myeloma. A total of 89 patients with 93 mobilizations were included. Apheresis was started when total white blood cell (WBC) count >10 × 10(9) /L for ID-CY/DOX and LD-CY groups and after eight doses of G-CSF (5 μg/kg twice daily) for G-CSF group. For five mobilizations in ID-CY/DOX group, the rate of successful mobilization (≥4.0 × 10(6) /kg CD34+ cells) was 80%. For 78 mobilizations in LD-CY group, the successful rate was 80.8%. For 10 mobilizations in the G-CSF group, the successful rate was 50%. The mean yield of CD34+ cells was higher in ID-CY/DOX and LD-CY groups as compared with that in G-CSF group (P = 0.026 and 0.020, respectively). There was no difference in the yield of CD34+ cells between ID-CY/DOX and LD-CY groups (P = 0.831). After autologous stem cell transplantation, the days to neutrophil and platelet engraftment were similar in these three groups (P = 0.713 and 0.821, respectively). In conclusion, we observed that ID-CY/DOX and LD-CY plus G-CSF for stem cell mobilization resulted in a higher successful rate and higher stem cell yields than G-CSF alone and their engraftment time were similar. Total WBC count >10 × 10(9) /L can be used as a guide to start apheresis in CY-based stem cell mobilization. J. Clin. Apheresis 31:423-428, 2016. © 2015 Wiley Periodicals, Inc.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
---|---|
Enthalten in: |
Journal of clinical apheresis - 31(2016), 5 vom: 04. Okt., Seite 423-8 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lin, Tung-Liang [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 03.04.2017 Date Revised 03.04.2017 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/jca.21421 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM252471369 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM252471369 | ||
003 | DE-627 | ||
005 | 20231224164202.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2016 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jca.21421 |2 doi | |
028 | 5 | 2 | |a pubmed24n0841.xml |
035 | |a (DE-627)NLM252471369 | ||
035 | |a (NLM)26340986 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lin, Tung-Liang |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.04.2017 | ||
500 | |a Date Revised 03.04.2017 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2015 Wiley Periodicals, Inc. | ||
520 | |a We retrospectively reviewed the results of cyclophosphamide (3 g/m(2) ), doxorubicin and dexamethasone plus granulocyte-colony stimulating factor (G-CSF) (ID-CY/DOX group), low-dose cyclophosphamide (2 g/m(2) ) plus G-CSF (LD-CY group) and G-CSF alone (G-CSF group) for stem cell mobilization in patients with multiple myeloma. A total of 89 patients with 93 mobilizations were included. Apheresis was started when total white blood cell (WBC) count >10 × 10(9) /L for ID-CY/DOX and LD-CY groups and after eight doses of G-CSF (5 μg/kg twice daily) for G-CSF group. For five mobilizations in ID-CY/DOX group, the rate of successful mobilization (≥4.0 × 10(6) /kg CD34+ cells) was 80%. For 78 mobilizations in LD-CY group, the successful rate was 80.8%. For 10 mobilizations in the G-CSF group, the successful rate was 50%. The mean yield of CD34+ cells was higher in ID-CY/DOX and LD-CY groups as compared with that in G-CSF group (P = 0.026 and 0.020, respectively). There was no difference in the yield of CD34+ cells between ID-CY/DOX and LD-CY groups (P = 0.831). After autologous stem cell transplantation, the days to neutrophil and platelet engraftment were similar in these three groups (P = 0.713 and 0.821, respectively). In conclusion, we observed that ID-CY/DOX and LD-CY plus G-CSF for stem cell mobilization resulted in a higher successful rate and higher stem cell yields than G-CSF alone and their engraftment time were similar. Total WBC count >10 × 10(9) /L can be used as a guide to start apheresis in CY-based stem cell mobilization. J. Clin. Apheresis 31:423-428, 2016. © 2015 Wiley Periodicals, Inc | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a autologous hematopoietic stem cell transplantation | |
650 | 4 | |a cyclophosphamide | |
650 | 4 | |a granulocyte-colony stimulating factor | |
650 | 4 | |a hematopoietic stem cell mobilization | |
650 | 4 | |a multiple myeloma | |
650 | 7 | |a Antigens, CD34 |2 NLM | |
650 | 7 | |a Granulocyte Colony-Stimulating Factor |2 NLM | |
650 | 7 | |a 143011-72-7 |2 NLM | |
650 | 7 | |a Dexamethasone |2 NLM | |
650 | 7 | |a 7S5I7G3JQL |2 NLM | |
650 | 7 | |a Doxorubicin |2 NLM | |
650 | 7 | |a 80168379AG |2 NLM | |
650 | 7 | |a Cyclophosphamide |2 NLM | |
650 | 7 | |a 8N3DW7272P |2 NLM | |
700 | 1 | |a Wang, Po-Nan |e verfasserin |4 aut | |
700 | 1 | |a Kuo, Ming-Chung |e verfasserin |4 aut | |
700 | 1 | |a Hung, Yu-Hsing |e verfasserin |4 aut | |
700 | 1 | |a Chang, Hung |e verfasserin |4 aut | |
700 | 1 | |a Tang, Tzung-Chih |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical apheresis |d 1993 |g 31(2016), 5 vom: 04. Okt., Seite 423-8 |w (DE-627)NLM012676969 |x 0733-2459 |7 nnns |
773 | 1 | 8 | |g volume:31 |g year:2016 |g number:5 |g day:04 |g month:10 |g pages:423-8 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jca.21421 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 31 |j 2016 |e 5 |b 04 |c 10 |h 423-8 |